300595 欧普康视
交易中 01-07 10:43:51
资讯
新帖
简况
欧普康视（300595）披露关于持股5%以上股东部分股份补充质押的公告，1月5日股价上涨8.58%
证券之星 · 01-05 22:16
欧普康视（300595）披露关于持股5%以上股东部分股份补充质押的公告，1月5日股价上涨8.58%
欧普康视最新公告：取得《药品生产许可证》
证券之星 · 01-05 20:20
欧普康视最新公告：取得《药品生产许可证》
股市必读：欧普康视（300595）12月30日董秘有最新回复
证券之星 · 2025-12-31
股市必读：欧普康视（300595）12月30日董秘有最新回复
欧普康视：公司业绩情况将在年报中披露
证券日报 · 2025-12-30
欧普康视：公司业绩情况将在年报中披露
欧普康视：参股公司计划近期推出音频类眼镜
证券之星 · 2025-12-30
欧普康视：参股公司计划近期推出音频类眼镜
欧普康视（300595）披露全资子公司对外提供财务资助的进展公告，12月26日股价下跌0.4%
证券之星 · 2025-12-26
欧普康视（300595）披露全资子公司对外提供财务资助的进展公告，12月26日股价下跌0.4%
欧普康视：截止到2025年12月19日股东总人数为61,914户
证券之星 · 2025-12-25
欧普康视：截止到2025年12月19日股东总人数为61,914户
欧普康视(300595)12月19日股东户数6.19万户，较上期减少0.02%
证券之星 · 2025-12-23
欧普康视(300595)12月19日股东户数6.19万户，较上期减少0.02%
欧普康视：眼科手术机器人处于临床试验阶段
证券之星 · 2025-12-23
欧普康视：眼科手术机器人处于临床试验阶段
欧普康视：盐酸毛果芸香碱滴眼液刚获临床试验批准
证券之星 · 2025-12-23
欧普康视：盐酸毛果芸香碱滴眼液刚获临床试验批准
欧普康视（300595）股东南京欧陶信息科技有限公司质押10000股，占总股本0%
证券之星 · 2025-12-18
欧普康视（300595）股东南京欧陶信息科技有限公司质押10000股，占总股本0%
欧普康视(300595)12月10日股东户数6.19万户，较上期增加0.08%
证券之星 · 2025-12-15
欧普康视(300595)12月10日股东户数6.19万户，较上期增加0.08%
欧普康视(300595.SZ)：盐酸毛果芸香碱滴眼液获得药物临床试验批准
智通财经 · 2025-12-05
欧普康视(300595.SZ)：盐酸毛果芸香碱滴眼液获得药物临床试验批准
欧普康视：参股企业将推音频类眼镜
证券之星 · 2025-12-04
欧普康视：参股企业将推音频类眼镜
欧普康视：巩膜镜目前还是自费产品
证券之星 · 2025-12-03
欧普康视：巩膜镜目前还是自费产品
欧普康视：截止到2025年11月28日股东总人数为61,877户
证券之星 · 2025-12-02
欧普康视：截止到2025年11月28日股东总人数为61,877户
欧普康视(300595)11月20日股东户数6.22万户，较上期减少1.11%
证券之星 · 2025-11-24
欧普康视(300595)11月20日股东户数6.22万户，较上期减少1.11%
欧普康视：前三季度视光终端收入占比提升至57.70%
证券之星 · 2025-11-19
欧普康视：前三季度视光终端收入占比提升至57.70%
股市必读：欧普康视（300595）11月14日董秘有最新回复
证券之星 · 2025-11-17
股市必读：欧普康视（300595）11月14日董秘有最新回复
欧普康视：离焦镜通过减少远视离焦减缓近视加深
证券之星 · 2025-11-14
欧普康视：离焦镜通过减少远视离焦减缓近视加深
加载更多
公司概况
公司名称：
欧普康视科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2017-01-17
主营业务：
欧普康视科技股份有限公司的主营业务是眼健康和近视防控技术与服务。公司的主要产品是硬性接触镜类及其护理产品、硬镜以外的其它视光产品、其它眼健康产品。
发行价格：
23.81
{"stockData":{"symbol":"300595","market":"SZ","secType":"STK","nameCN":"欧普康视","latestPrice":15.81,"timestamp":1767753831000,"preClose":16.22,"halted":0,"volume":12076255,"delay":0,"changeRate":-0.0253,"floatShares":668000000,"shares":894999999,"eps":0.5493,"marketStatus":"交易中","change":-0.41,"latestTime":"01-07 10:43:51","open":16.14,"high":16.17,"low":15.75,"amount":192000000,"amplitude":0.0259,"askPrice":15.82,"askSize":206,"bidPrice":15.81,"bidSize":2112,"shortable":0,"etf":0,"ttmEps":0.5493,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1767756600000},"marketStatusCode":2,"adr":0,"adjPreClose":16.22,"symbolType":"stock","openAndCloseTimeList":[[1767749400000,1767756600000],[1767762000000,1767769200000]],"highLimit":17.84,"lowLimit":14.6,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":895289123,"isCdr":false,"pbRate":2.94,"roa":"--","peRate":28.782086,"roe":"9.13%","epsLYR":0.6408,"committee":0.66193,"marketValue":14155000000,"turnoverRate":0.0181,"status":1,"floatMarketCap":10569000000},"requestUrl":"/m/hq/s/300595","defaultTab":"news","newsList":[{"id":"2601688786","title":"欧普康视（300595）披露关于持股5%以上股东部分股份补充质押的公告，1月5日股价上涨8.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688786","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601688786?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:16","pubTimestamp":1767622601,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，欧普康视报收于15.95元，较前一交易日上涨8.58%，最新总市值为142.8亿元。该股当日开盘14.77元，最高16.23元，最低14.75元，成交额达5.78亿元，换手率为5.51%。公司于近日发布公告，持股5%以上股东南京欧陶信息科技有限公司将其持有的10,000股公司股份补充质押给招商证券股份有限公司，质押起始日为2025年12月31日，到期日为办理解除质押登记手续之日。本次质押占南京欧陶所持股份比例的0.01%，占公司总股本比例0.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500039986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2601886091","title":"欧普康视最新公告：取得《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886091","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601886091?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:20","pubTimestamp":1767615630,"startTime":"0","endTime":"0","summary":"欧普康视(300595.SZ)公告称，公司近日收到安徽省药品监督管理局颁发的《药品生产许可证》。许可证编号皖20250658，有效期至2030年12月25日。公司表示，该许可证的取得有利于优化产品结构，对长远发展有积极推动作用，但短期内不会对经营业绩产生重大影响。公司还需通过在研产品注册申报、现场核查及药品GMP符合性检查等程序，并取得《药品注册证》后，方可进行商业化生产销售。医药产品的生产、销售受行业政策、市场环境等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500036224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2595111137","title":"股市必读：欧普康视（300595）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595111137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595111137?lang=zh_cn&edition=full","pubTime":"2025-12-31 02:16","pubTimestamp":1767118574,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，欧普康视报收于14.78元，下跌0.67%，换手率0.88%，成交量5.9万手，成交额8757.14万元。董秘最新回复投资者： 请问贵公司今年业绩同比去年怎样？当日关注点来自交易信息汇总：12月30日主力资金净流出1415.63万元，显示主力资金呈明显离场态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100001875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2595779046","title":"欧普康视：公司业绩情况将在年报中披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779046","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595779046?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:41","pubTimestamp":1767102060,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月30日，欧普康视在互动平台回答投资者提问时表示，公司业绩情况将在年报中披露。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-30/doc-inhequpm5713578.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-30/doc-inhequpm5713578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2595763335","title":"欧普康视：参股公司计划近期推出音频类眼镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763335","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595763335?lang=zh_cn&edition=full","pubTime":"2025-12-30 11:34","pubTimestamp":1767065677,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：为什么贵公司参股的智能眼镜，市场没人宣传？是不是不喜欢让消费者买到？欧普康视回复：您好，参股公司计划近期先推出音频类眼镜，待正式推出后进行相关的宣传工作。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000016151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2594294704","title":"欧普康视（300595）披露全资子公司对外提供财务资助的进展公告，12月26日股价下跌0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594294704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594294704?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:55","pubTimestamp":1766760913,"startTime":"0","endTime":"0","summary":"公司于近日发布关于全资子公司对外提供财务资助的进展公告。公告显示，欧普康视科技股份有限公司于2024年3月29日审议通过全资子公司欧普投资向参股公司上海瑞影提供400万元财务资助的议案，借款期限至2025年12月31日，利率分为无息或单利10%，资金分批划转。截至公告日，欧普投资已收到上海瑞影归还的全部财务资助款项400万元，本次财务资助已全部收回。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2594816742","title":"欧普康视：截止到2025年12月19日股东总人数为61,914户","url":"https://stock-news.laohu8.com/highlight/detail?id=2594816742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594816742?lang=zh_cn&edition=full","pubTime":"2025-12-25 11:33","pubTimestamp":1766633593,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司，现在股份人数是多少？欧普康视回复：您好，截止到2025年12月19日，公司股东总人数为61,914户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500013540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2593664496","title":"欧普康视(300595)12月19日股东户数6.19万户，较上期减少0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593664496","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593664496?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:49","pubTimestamp":1766483390,"startTime":"0","endTime":"0","summary":"证券之星消息，近日欧普康视披露，截至2025年12月19日公司股东户数为6.19万户，较12月10日减少15.0户，减幅为0.02%。在医疗器械行业个股中，欧普康视股东户数高于行业平均水平，截至12月19日，医疗器械行业平均股东户数为2.19万户。从股价来看，2025年12月10日至2025年12月19日，欧普康视区间跌幅为2.91%，在此期间股东户数减少15.0户，减幅为0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300028646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2593868462","title":"欧普康视：眼科手术机器人处于临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2593868462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593868462?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:04","pubTimestamp":1766473482,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，公司参股迪视医疗公司开发的眼科手术机器人，以及参股哈工艾斯德康公司开发的陪伴机器人，目前是否已上市？推广情况市场反应如何？欧普康视回复：您好，公司参股基金投资迪视医疗开发的眼科手术机器人，目前处于临床试验阶段；参股基金投资哈工艾斯德康开发的陪伴机器人，目前处于工程样机开发和验证阶段。目前两款产品尚未正式上市。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2593145443","title":"欧普康视：盐酸毛果芸香碱滴眼液刚获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593145443","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593145443?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:03","pubTimestamp":1766451792,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，贵司盐酸毛果芸香碱滴眼液获批，请问预计2026年销售渠道主要有哪些？目前该类滴眼液市场情况如何？该产品获批上市预计对提升业绩是否有较大帮助？贵司对于同类老龄滴眼液如玻璃酸钠等是否有相关进度和安排？谢谢！欧普康视回复：您好，盐酸毛果芸香碱滴眼液刚获得临床试验批准，谈上市还早。药品的进展会按照规则披露。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300006402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2592977344","title":"欧普康视（300595）股东南京欧陶信息科技有限公司质押10000股，占总股本0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592977344","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592977344?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:47","pubTimestamp":1766054836,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视12月18日公开信息显示，股东南京欧陶信息科技有限公司向招商证券股份有限公司合计质押1.0万股，占总股本0.0%。质押详情见下表：截止本公告日，股东南京欧陶信息科技有限公司已累计质押股份6830.5万股，占其持股总数的67.99%，股东合肥欧普民生投资管理合伙企业已累计质押股份350.0万股，占其持股总数的12.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800029148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2591121256","title":"欧普康视(300595)12月10日股东户数6.19万户，较上期增加0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591121256","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591121256?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:48","pubTimestamp":1765792080,"startTime":"0","endTime":"0","summary":"证券之星消息，近日欧普康视披露，截至2025年12月10日公司股东户数为6.19万户，较11月28日增加52.0户，增幅为0.08%。在医疗器械行业个股中，欧普康视股东户数高于行业平均水平，截至12月10日，医疗器械行业平均股东户数为2.19万户。从股价来看，2025年11月28日至2025年12月10日，欧普康视区间跌幅为1.53%，在此期间股东户数增加52.0户，增幅为0.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2589860774","title":"欧普康视(300595.SZ)：盐酸毛果芸香碱滴眼液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860774?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:00","pubTimestamp":1764925250,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧普康视(300595.SZ)发布公告，公司于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》(通知书编号：2025LP03261)，批准公司的“盐酸毛果芸香碱滴眼液”开展临床试验。据悉，盐酸毛果芸香碱是M-胆碱受体激动剂，可激活平滑肌(例如虹膜括约肌和睫状肌)的毒蕈碱受体，通过虹膜括约肌的收缩，使瞳孔收缩，以增加焦深，改善近中视力，同时保持瞳孔对光的反应，另外其还可收缩睫状肌，增强适应力，从而达到治疗成人老花眼的效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"欧普康视(300595.SZ)：盐酸毛果芸香碱滴眼液获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2588722260","title":"欧普康视：参股企业将推音频类眼镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722260","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588722260?lang=zh_cn&edition=full","pubTime":"2025-12-04 11:36","pubTimestamp":1764819380,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司AI眼镜.AI镜片研发进行到哪一步了，什么时候回上市！欧普康视回复：您好，公司参股的智能眼镜企业计划近期先推出可以日常佩戴使用的音频类眼镜。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400013393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2588060151","title":"欧普康视：巩膜镜目前还是自费产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2588060151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588060151?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:48","pubTimestamp":1764722891,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：巩膜镜多用于矫正超高度近视（±2500度内）、圆锥角膜、角膜移植术后不规则散光及中重度干眼症。请问巩膜镜会不会列入上海、深圳或者广州的惠民保范围？公司在这方面可否做些工作？谢谢。欧普康视回复：您好，巩膜镜目前还是自费产品，是否能列入部分城市的惠民保范围，我们联合当地合作伙伴了解一下。谢谢您的建议！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300004393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2588977085","title":"欧普康视：截止到2025年11月28日股东总人数为61,877户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588977085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588977085?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:36","pubTimestamp":1764646587,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视(300595)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：截止11月底股东人数？欧普康视回复：您好，截止到2025年11月28日，公司股东总人数为61,877户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200012936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2585468925","title":"欧普康视(300595)11月20日股东户数6.22万户，较上期减少1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468925","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468925?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:50","pubTimestamp":1763977828,"startTime":"0","endTime":"0","summary":"证券之星消息，近日欧普康视披露，截至2025年11月20日公司股东户数为6.22万户，较11月10日减少700.0户，减幅为1.11%。在医疗器械行业个股中，欧普康视股东户数高于行业平均水平，截至11月20日，医疗器械行业平均股东户数为2.2万户。从股价来看，2025年11月10日至2025年11月20日，欧普康视区间跌幅为3.37%，在此期间股东户数减少700.0户，减幅为1.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2584391913","title":"欧普康视：前三季度视光终端收入占比提升至57.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584391913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584391913?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:45","pubTimestamp":1763541912,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视11月19日在投资者关系平台上答复投资者关心的问题。欧普康视回复：您好，前三季度公司控股的视光终端收入占总收入的比已从去年同期的53.01%提升至57.70%，终端数量也在增加；普通眼镜店取得巩膜镜零售资质可以配镜，不过，目前我们还是先重点开发专业视光渠道，因为他们技术力量较强，上手快；对于具备专业视光技术人员的非医疗视光服务机构，我们将强化培训巩膜镜验配技术，达到技术规范要求后将授权开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900026027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0},{"id":"2584693447","title":"股市必读：欧普康视（300595）11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584693447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584693447?lang=zh_cn&edition=full","pubTime":"2025-11-17 03:29","pubTimestamp":1763321351,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，欧普康视报收于17.07元，下跌0.76%，换手率1.38%，成交量9.2万手，成交额1.58亿元。交易信息汇总资金流向11月14日主力资金净流出490.95万元；游资资金净流入505.38万元；散户资金净流出14.44万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700001213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300595"],"gpt_icon":0},{"id":"2583528697","title":"欧普康视：离焦镜通过减少远视离焦减缓近视加深","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528697?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091423,"startTime":"0","endTime":"0","summary":"证券之星消息，欧普康视11月14日在投资者关系平台上答复投资者关心的问题。这种减缓近视加深的机制最早来自于角膜塑形镜，其夜间配戴后在角膜上留下了一个“离焦环”，起到了减少周边远视离焦的作用，由于这个”离焦环”固定在角膜上，用眼时一直起作用，效果优于其它减离焦产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300595","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767753834288,"stockEarnings":[{"period":"1week","weight":0.0974},{"period":"1month","weight":0.0391},{"period":"3month","weight":-0.051},{"period":"6month","weight":0.0413},{"period":"1year","weight":-0.0414},{"period":"ytd","weight":0.1042}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.1635},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"欧普康视科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"61914人(较上一季度减少0.02%)","perCapita":"10797股","listingDate":"2017-01-17","address":"安徽省合肥市蜀山区高新区望江西路4899号","registeredCapital":"89528万元","survey":" 欧普康视科技股份有限公司的主营业务是眼健康和近视防控技术与服务。公司的主要产品是硬性接触镜类及其护理产品、硬镜以外的其它视光产品、其它眼健康产品。","listedPrice":23.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧普康视(300595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧普康视(300595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧普康视,300595,欧普康视股票,欧普康视股票老虎,欧普康视股票老虎国际,欧普康视行情,欧普康视股票行情,欧普康视股价,欧普康视股市,欧普康视股票价格,欧普康视股票交易,欧普康视股票购买,欧普康视股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧普康视(300595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧普康视(300595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}